CD14 and breast cancer: Additionally, Bergenfelz et al. (92), reported an expansion of circulating CD14+HLA-DR−/low M-MDSCs in patients with locoregional recurrence or metastatic BC, which was correlated with increased metastasis to lymph nodes and visceral organs, suggesting that circulating M-MDSCs could be a potential biomarker for disease progression and a guide to individualize efficient immunomodulatory treatments.